CN113689931B - Auxiliary system and method for taking medicine - Google Patents
Auxiliary system and method for taking medicine Download PDFInfo
- Publication number
- CN113689931B CN113689931B CN202110999179.6A CN202110999179A CN113689931B CN 113689931 B CN113689931 B CN 113689931B CN 202110999179 A CN202110999179 A CN 202110999179A CN 113689931 B CN113689931 B CN 113689931B
- Authority
- CN
- China
- Prior art keywords
- composition
- event
- driven
- medication
- endometrial
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 239000003814 drug Substances 0.000 title claims abstract description 123
- 238000000034 method Methods 0.000 title claims description 28
- 239000000203 mixture Substances 0.000 claims abstract description 129
- 230000002357 endometrial effect Effects 0.000 claims abstract description 52
- 230000000737 periodic effect Effects 0.000 claims abstract description 32
- 208000028017 Psychotic disease Diseases 0.000 claims abstract description 30
- 239000002858 neurotransmitter agent Substances 0.000 claims abstract description 12
- 210000002569 neuron Anatomy 0.000 claims abstract description 8
- 210000002249 digestive system Anatomy 0.000 claims abstract description 5
- 229940079593 drug Drugs 0.000 claims description 62
- 210000004696 endometrium Anatomy 0.000 claims description 32
- 230000035790 physiological processes and functions Effects 0.000 claims description 26
- 230000035755 proliferation Effects 0.000 claims description 18
- 230000008569 process Effects 0.000 claims description 17
- 230000000694 effects Effects 0.000 claims description 13
- 206010051909 Endometrial atrophy Diseases 0.000 claims description 10
- 206010043268 Tension Diseases 0.000 claims description 5
- 208000012287 Prolapse Diseases 0.000 claims description 3
- 238000006073 displacement reaction Methods 0.000 claims description 3
- 230000000977 initiatory effect Effects 0.000 claims description 3
- 230000001143 conditioned effect Effects 0.000 claims description 2
- 230000008447 perception Effects 0.000 claims description 2
- 238000011269 treatment regimen Methods 0.000 claims 2
- 230000002596 correlated effect Effects 0.000 claims 1
- 230000036962 time dependent Effects 0.000 claims 1
- 230000003340 mental effect Effects 0.000 abstract description 10
- 210000005036 nerve Anatomy 0.000 abstract description 4
- 230000008859 change Effects 0.000 description 27
- 230000006399 behavior Effects 0.000 description 22
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 15
- 201000010099 disease Diseases 0.000 description 14
- 208000024891 symptom Diseases 0.000 description 8
- 230000006996 mental state Effects 0.000 description 6
- 230000028327 secretion Effects 0.000 description 6
- 208000007443 Neurasthenia Diseases 0.000 description 5
- 230000002159 abnormal effect Effects 0.000 description 5
- 206010003549 asthenia Diseases 0.000 description 5
- 230000007774 longterm Effects 0.000 description 5
- 230000008506 pathogenesis Effects 0.000 description 5
- 206010000117 Abnormal behaviour Diseases 0.000 description 4
- 238000002679 ablation Methods 0.000 description 4
- 208000020016 psychiatric disease Diseases 0.000 description 4
- 238000012549 training Methods 0.000 description 4
- 230000003542 behavioural effect Effects 0.000 description 3
- 230000005540 biological transmission Effects 0.000 description 3
- 230000002996 emotional effect Effects 0.000 description 3
- 230000005906 menstruation Effects 0.000 description 3
- 238000012544 monitoring process Methods 0.000 description 3
- 239000008194 pharmaceutical composition Substances 0.000 description 3
- 230000035479 physiological effects, processes and functions Effects 0.000 description 3
- 206010003694 Atrophy Diseases 0.000 description 2
- QVZGAIWUSYVGBJ-UHFFFAOYSA-N Cycloartenyl ferulate Natural products CCC12CCC3(C)C(C(C)CCC=C(C)C)CCC3(C)C1CCC(C1(C)C)C2CCC1OC(=O)C=CC1=CC=C(O)C(OC)=C1 QVZGAIWUSYVGBJ-UHFFFAOYSA-N 0.000 description 2
- 241000628997 Flos Species 0.000 description 2
- JBSUVXVGZSMGDJ-YVMHCORFSA-N Oryzanol C Chemical compound C1=C(O)C(OC)=CC(\C=C\C(=O)O[C@@H]2C([C@@H]3CC[C@H]4[C@]5(C)CC[C@@H]([C@@]5(C)CC[C@@]54C[C@@]53CC2)[C@H](C)CCC(=C)C(C)C)(C)C)=C1 JBSUVXVGZSMGDJ-YVMHCORFSA-N 0.000 description 2
- 238000009825 accumulation Methods 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 230000037444 atrophy Effects 0.000 description 2
- 238000004891 communication Methods 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 125000004122 cyclic group Chemical group 0.000 description 2
- FODTZLFLDFKIQH-UHFFFAOYSA-N cycloartenol trans-ferulate Natural products C1=C(O)C(OC)=CC(C=CC(=O)OC2C(C3CCC4C5(C)CCC(C5(C)CCC54CC53CC2)C(C)CCC=C(C)C)(C)C)=C1 FODTZLFLDFKIQH-UHFFFAOYSA-N 0.000 description 2
- 238000013461 design Methods 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 238000003745 diagnosis Methods 0.000 description 2
- 238000010586 diagram Methods 0.000 description 2
- 230000008451 emotion Effects 0.000 description 2
- 239000000284 extract Substances 0.000 description 2
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 description 2
- 230000037406 food intake Effects 0.000 description 2
- 239000012634 fragment Substances 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- FODTZLFLDFKIQH-FSVGXZBPSA-N gamma-Oryzanol (TN) Chemical compound C1=C(O)C(OC)=CC(\C=C\C(=O)O[C@@H]2C([C@@H]3CC[C@H]4[C@]5(C)CC[C@@H]([C@@]5(C)CC[C@@]54C[C@@]53CC2)[C@H](C)CCC=C(C)C)(C)C)=C1 FODTZLFLDFKIQH-FSVGXZBPSA-N 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 230000003993 interaction Effects 0.000 description 2
- 230000010534 mechanism of action Effects 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 201000000980 schizophrenia Diseases 0.000 description 2
- 230000001624 sedative effect Effects 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- GIPOFCXYHMWROH-UHFFFAOYSA-L 2-aminoacetate;iron(2+) Chemical compound [Fe+2].NCC([O-])=O.NCC([O-])=O GIPOFCXYHMWROH-UHFFFAOYSA-L 0.000 description 1
- 208000017194 Affective disease Diseases 0.000 description 1
- 241000218993 Begonia Species 0.000 description 1
- 240000009138 Curcuma zedoaria Species 0.000 description 1
- 235000003405 Curcuma zedoaria Nutrition 0.000 description 1
- 208000020401 Depressive disease Diseases 0.000 description 1
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1
- 208000004547 Hallucinations Diseases 0.000 description 1
- PWKSKIMOESPYIA-BYPYZUCNSA-N L-N-acetyl-Cysteine Chemical compound CC(=O)N[C@@H](CS)C(O)=O PWKSKIMOESPYIA-BYPYZUCNSA-N 0.000 description 1
- RHGKLRLOHDJJDR-BYPYZUCNSA-N L-citrulline Chemical compound NC(=O)NCCC[C@H]([NH3+])C([O-])=O RHGKLRLOHDJJDR-BYPYZUCNSA-N 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
- 206010026749 Mania Diseases 0.000 description 1
- 208000019022 Mood disease Diseases 0.000 description 1
- OVBPIULPVIDEAO-UHFFFAOYSA-N N-Pteroyl-L-glutaminsaeure Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-UHFFFAOYSA-N 0.000 description 1
- GIYXAJPCNFJEHY-UHFFFAOYSA-N N-methyl-3-phenyl-3-[4-(trifluoromethyl)phenoxy]-1-propanamine hydrochloride (1:1) Chemical compound Cl.C=1C=CC=CC=1C(CCNC)OC1=CC=C(C(F)(F)F)C=C1 GIYXAJPCNFJEHY-UHFFFAOYSA-N 0.000 description 1
- RHGKLRLOHDJJDR-UHFFFAOYSA-N Ndelta-carbamoyl-DL-ornithine Natural products OC(=O)C(N)CCCNC(N)=O RHGKLRLOHDJJDR-UHFFFAOYSA-N 0.000 description 1
- 206010039897 Sedation Diseases 0.000 description 1
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 1
- 208000010513 Stupor Diseases 0.000 description 1
- 206010046764 Uterine atrophy Diseases 0.000 description 1
- 230000006578 abscission Effects 0.000 description 1
- 229960004308 acetylcysteine Drugs 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 230000016571 aggressive behavior Effects 0.000 description 1
- 239000003693 atypical antipsychotic agent Substances 0.000 description 1
- 229940127236 atypical antipsychotics Drugs 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 210000005013 brain tissue Anatomy 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 235000013477 citrulline Nutrition 0.000 description 1
- 229960002173 citrulline Drugs 0.000 description 1
- 239000001812 curcuma zedoaria berg. rosc. Substances 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 238000007405 data analysis Methods 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 229960000389 fluoxetine hydrochloride Drugs 0.000 description 1
- 229960000304 folic acid Drugs 0.000 description 1
- 235000019152 folic acid Nutrition 0.000 description 1
- 239000011724 folic acid Substances 0.000 description 1
- 235000013922 glutamic acid Nutrition 0.000 description 1
- 239000004220 glutamic acid Substances 0.000 description 1
- 229960002989 glutamic acid Drugs 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 206010022437 insomnia Diseases 0.000 description 1
- NLYAJNPCOHFWQQ-UHFFFAOYSA-N kaolin Chemical compound O.O.O=[Al]O[Si](=O)O[Si](=O)O[Al]=O NLYAJNPCOHFWQQ-UHFFFAOYSA-N 0.000 description 1
- 230000003907 kidney function Effects 0.000 description 1
- 239000011021 lapis lazuli Substances 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 230000003908 liver function Effects 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 230000007257 malfunction Effects 0.000 description 1
- 238000010339 medical test Methods 0.000 description 1
- 238000002483 medication Methods 0.000 description 1
- 206010027175 memory impairment Diseases 0.000 description 1
- 230000002175 menstrual effect Effects 0.000 description 1
- 201000003102 mental depression Diseases 0.000 description 1
- 230000001483 mobilizing effect Effects 0.000 description 1
- 230000036651 mood Effects 0.000 description 1
- CDBRNDSHEYLDJV-FVGYRXGTSA-M naproxen sodium Chemical compound [Na+].C1=C([C@H](C)C([O-])=O)C=CC2=CC(OC)=CC=C21 CDBRNDSHEYLDJV-FVGYRXGTSA-M 0.000 description 1
- 229960003940 naproxen sodium Drugs 0.000 description 1
- 238000010606 normalization Methods 0.000 description 1
- 235000020939 nutritional additive Nutrition 0.000 description 1
- 230000027758 ovulation cycle Effects 0.000 description 1
- 238000003909 pattern recognition Methods 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 231100000572 poisoning Toxicity 0.000 description 1
- 230000000607 poisoning effect Effects 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 238000001671 psychotherapy Methods 0.000 description 1
- 239000009806 pulsatillae Substances 0.000 description 1
- 238000010298 pulverizing process Methods 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 230000033764 rhythmic process Effects 0.000 description 1
- 230000036280 sedation Effects 0.000 description 1
- 210000000582 semen Anatomy 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- 229960001790 sodium citrate Drugs 0.000 description 1
- 235000011083 sodium citrates Nutrition 0.000 description 1
- 238000005507 spraying Methods 0.000 description 1
- 238000013268 sustained release Methods 0.000 description 1
- 239000012730 sustained-release form Substances 0.000 description 1
- 210000000225 synapse Anatomy 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 239000010681 turmeric oil Substances 0.000 description 1
- 231100001042 uterine atrophy Toxicity 0.000 description 1
- 238000012795 verification Methods 0.000 description 1
- 239000002699 waste material Substances 0.000 description 1
- 235000019509 white turmeric Nutrition 0.000 description 1
- 210000000707 wrist Anatomy 0.000 description 1
Classifications
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
- G16H20/00—ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance
- G16H20/10—ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance relating to drugs or medications, e.g. for ensuring correct administration to patients
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
- G16H70/00—ICT specially adapted for the handling or processing of medical references
- G16H70/40—ICT specially adapted for the handling or processing of medical references relating to drugs, e.g. their side effects or intended usage
Landscapes
- Engineering & Computer Science (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Chemical & Material Sciences (AREA)
- Medical Informatics (AREA)
- Primary Health Care (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Toxicology (AREA)
- Medical Treatment And Welfare Office Work (AREA)
Abstract
The invention provides a medicine taking auxiliary system which comprises a medicine for treating periodic psychosis and a storage device for storing the medicine. A medicament for periodic psychosis comprising a first composition that is ingested by the digestive system slowly before and after endometrial shedding in a manner that reduces nerve tension in conjunction with metacerebral neurons and a second composition that reduces mental activity in conjunction with neurotransmitters during endometrial shedding, wherein the storage device is configured to graphically provide a user with event-driven advice of taking the medicament that is predictive of endometrial shedding by the administration assistance system, wherein the first composition event-driven advice of taking the medicament constitutes a time-limited execution condition of the event-driven advice of taking the medicament of the second composition.
Description
Technical Field
The invention relates to the field of medical machinery, in particular to an auxiliary system and method for taking medicine.
Background
Mental disorders with periodic attacks on a monthly basis are called periodic mental disorders. The reasons are unknown and may be related to a malfunction of the brain. The disease is a disease of female, and is caused by puberty. The symptoms of this disease can be divided into two categories. One type is manifested by mental excitement, increased speech, increased emotion, shouting running, etc. The other group has disturbance of consciousness, has the illusion of fragments and fragments, is dull and whisper, and even has stupor. Forgetfulness is common after the onset. Most of the mental symptoms of the periodic psychosis are better than those of the first days of menstruation after 1-2 weeks, and are less than those at the end of menstruation, but no patients have the first half of menstrual cycle. The relationship between each occurrence of the same patient and menstruation is consistent.
The Chinese patent with publication number CN102008688B relates to a medicine for treating periodic psychosis, which is prepared by the following method: decocting radix Paeoniae Rubra 8-12 parts and radix et rhizoma Rhei 7.5-10.5 parts twice, and concentrating the filtrate to obtain extract; pulverizing radix et rhizoma Rhei 0.5-1.5 parts into fine powder of 80-120 mesh, mixing with above extract; mixing the above fine powder with diluent and binder; uniformly spraying 0.02-0.03ml of zedoary turmeric oil onto the above granule, and mixing; adding lubricant into the above granule, and tabletting. Further, the Chinese patent with publication number of CN105233029A relates to a Chinese and Western medicine compound preparation for treating menstrual periodic psychosis, which is prepared from traditional Chinese medicine components and western medicine components, wherein the traditional Chinese medicine components are mainly prepared by extracting the following raw materials: herba Centellae, radix Callicarpae Formosanae, radix Pulsatillae stem and leaf, herba Lespedezae Bicoloris, flos Mangiferae Indicae, phasian Begonia sheet, radix et rhizoma Tianjiaoti, caulis Ardisiae Japonicae, semen Livistonae chinensis, lapis Micae aureus, herba Potentillae chinensis, herba Arenariae Chamomillae, radix et rhizoma Cunninghamiae Lanceolatae, flos Magnoliae officinalis, halloysitum rubrum, radix et rhizoma Myricae Rubrae, herba Agrimoniae, radix Musae, radix Cymbopogonis Citrari, herba Celastri Graminei, and radix et rhizoma Babylonicae; the western medicine comprises the following components: fluoxetine hydrochloride, N-acetylcysteine, naproxen sodium, glutamic acid, citrulline, sodium citrate, iron glycinate, folic acid and a nutritional additive. The medicine combination in the patent treats diseases through Chinese medicine and Chinese and Western compound medicine, but aiming at the disease characteristics of periodic psychosis, the medicine combination is not treated by adopting the guidelines of 'disease strong medicine control and disease warm medicine prevention', and long-time psychotherapy leads the normal mental state of a patient in a disease state to be interfered by medicine, and long-term mental depression and other problems are easy to be induced.
Aiming at the sedation of mental state in the disease course, chinese patent publication No. CN101313908B discloses a composition taking cycloartenyl ferulate and 24-methylene cycloartenyl ferulate as active ingredients, wherein the sum of the contents of cycloartenyl ferulate and 24-methylene cycloartenyl ferulate accounts for more than 90% of the total active ingredients. The composition can be used for sedating patients with periodic mental disease. The present invention proposes a drug for controlling the behavior of a patient in an onset period, but the drug depends on the behavior control of a sedative effect, requires a long-term administration by the patient, and has little effect on the effect of curing a disease.
Therefore, it is desirable to design a medication assistance system that can be directed to a pharmaceutical composition of a periodic mental patient in the onset and non-onset phases and a system that can assist the patient in taking the pharmaceutical composition.
Furthermore, there are differences in one aspect due to understanding to those skilled in the art; on the other hand, as the inventors studied numerous documents and patents while the present invention was made, the text is not limited to details and contents of all that are listed, but it is by no means the present invention does not have these prior art features, the present invention has all the prior art features, and the applicant remains in the background art to which the rights of the related prior art are added.
Disclosure of Invention
In view of the shortcomings of the prior art, the present invention contemplates a medication assistance system for the treatment of periodic psychosis and a storage device for storing the medication. A medicament for periodic psychosis comprises a first composition that is slowly taken up by the digestive system before and after endometrial shedding in a way that binds to the metaencephalic neurons to slow down the nervous tension and a second composition that reduces mental activity in the way that binds to neurotransmitters during endometrial shedding. The storage means graphically provides to the user an event-driven medication recommendation consisting of an endometrial drop predicted by the medication assistance system, wherein the first composition event-driven medication recommendation constitutes a time-limited execution condition for the second composition event-driven medication recommendation.
The technical proposal has the advantages that: a female population frequently develops with periodic psychosis, and occurs with female endometrial changes. The peak onset of periodic psychosis is in the process of endometrial shedding, in which abnormal secretion of neurotransmitters occurs in patients, thereby causing abnormal activation of neurons. After the endometrial shedding process is completed, neurotransmitters resume normal activity and cause neurasthenia based on the normalization of overactive neurons. Periodic psychosis is a circulating pathogenesis, so medication advice can be arranged with an event as a driver. In the normal period, the first composition is combined with the metacerebral neurons to alleviate the nervous tension and reduce the occurrence of symptoms of neurasthenia by taking the first composition for the purpose of preventing and alleviating side effects after onset. Upon entering the abnormal period, a recommendation for taking the second composition is made with the aim of reducing secretion of neurotransmitters. Preferably, the second composition can be an atypical antipsychotic. The first composition can be oryzanol.
The first composition reduces the nervous tension before and after endometrial ablation in a manner that binds to metacerebral neurons. The first composition is ingested by the digestive system in a sustained release manner. Based on the mechanism of action of the first composition, it can be set to be taken once a single day and to be slowly released into the human body within 24 hours, thereby maintaining the nerve normal state of the human body. The second composition reduces mental activity during endometrial ablation in a manner that binds neurotransmitters. Based on the mechanism of action of the second composition, during the onset of symptoms like schizophrenia are mainly caused by abnormal neurotransmitter secretion, and thus the ingestion of the second composition is required to interfere with neurotransmitter secretion or binding to the nerve synapses, thereby reducing abnormal activity of nerve thinking. The storage device is used for storing the first composition and the second composition and providing advice for the user to take the medicine. The advice of taking medicine can be realized by means of voice, image, vibration or light change, etc. The storage device provides advice to the user to take the medication. Event driven refers to a strategy for making decisions in the process of continuous transaction management, namely, following events occurring at the current time point, mobilizing available resources and executing related tasks, so that the problem of continuous occurrence is solved. The medication recommendations are event-driven, which consist of endometrial casts predicted by the medication assistance system. The physiological state change node of the endometrium is an anchor point, so that the storage device performs research and judgment and instruction sending aiming at the current state. Further, the first composition event-driven medication intake recommendation is used as a time-limited execution condition to limit the event-driven medication recommendation of the second composition. During a change in the physiological state of the patient, uterine proliferation and uterine atrophy occur before the womb is shed, so that the recommended administration of the first composition, which is driven by the physiological state of endometrial proliferation and endometrial atrophy, is preferentially performed, and after this execution is ended, the recommended administration of the second composition is driven based on the initiation of the physiological state of endometrial shed.
The node of the administration switch can be based on a determination of the presence of endometrium, with a change in the state of endometrium as a driving condition, the storage providing instructions triggering the administration of the first composition and the second composition advice. The node selection of the medicine composition taking suggestion is accompanied with the change of the endometrial existence state, so that the taking of the first composition and the second composition is in the same track with the change of the endometrial physiological state, and the taking of the first composition and the second composition is indirectly in the same track with the periodical psychosis pathogenesis progress of a patient, thereby achieving the effect of pertinently reducing the pathogenesis symptoms by taking the physiological state of endometrial abscission as an anchor point at the periodical psychosis pathogenesis peak. The ingestion of the first composition is performed with a low efficacy in the non-onset course with the aim of alleviating the negative effects of onset and reducing neurasthenia.
In the case of periodic psychosis, the patient, at least upon entering endometrial casts, develops a different and less intelligent behaviour than usual, accompanied by a lack of self-management ability, is unable to evaluate, manage and predict the symptomatic development of his own behaviour; their treatment is not only dependent on pharmacological measures, but also requires behavioural management. While personal mood management disorders resulting from caregivers or guardians who have patients with periodic psychosis often constitute a critical issue in the care of patients with periodic psychosis due to the long-term observation of their medications and the care to manage their behavior. In the prior art, the use of intelligent devices with "no emotion, no emotional feedback" for assisting treatment is a common technical measure, however, the lack of interest in learning such devices by patients and families even shows extreme objection, and thus has not gained popularity. Based on the above, the present invention is directed to a patient and caretaker to regularly train the patient to develop a specific taking behavior habit in a manner that the patient and caretaker take special means to generate the taking action that the patient and caretaker must face. Further, the taking measures that the patient and caretaker must face can be made to interact with the patient without being affected by "emotional" fluctuations, achieving normative operation. The individual patient relies on the training of the first and second compositions in such a way that the two types of effects of the compositions promote each other and the conditions of the administration form conditions for each other, so that the problems of treatment and behavior prominence of the individual patient themselves are optimized. Based on the unique requirements of the first and second compositions on the efficacy and the condition of administration, the administration scheme of the two compositions which are mutually restricted in time and are carried out by taking the physiological state of endometrium as an anchor point is selected, so that the administration scheme capable of generating behavior training for patients is balanced between complex and accurate behavior treatment, and is accepted and used by most patients and caregivers in extensive experiments and tests with excellent performance. Although the first and second compositions need to be administered in a strict adherence to a specific time to achieve the optimal therapeutic effect, in the case that the administration conditions between the two are not achieved, the first composition and the time condition play a role in behavioral training or therapy more as long as the patient can administer the second composition during the physiological period (the physiological period can generate features which are significantly different from other periods and can help the patient distinguish the administration period of the second composition), the patient condition caused by serious treatment accidents is not controlled. In addition, the second composition of the present invention is distinguished from the long-term administration of other mental drugs, and is selected to be administered when discomfort and obvious physiological characteristics are generated in the human body, so that the administration mode of the first composition is significantly different from the administration mode of the second composition (such as a tablet), particularly the administration mode of the first composition is in compliance with the normal mental state of the patient, and therefore, the image acquisition mode is sufficient to distinguish the behavior distinction of the two. Therefore, the medicine storage system does not need a large amount of high-precision data analysis and behavior pattern recognition, does not need complex and expensive biological sensors, and is particularly suitable for families of mental patients with extremely high disease-induced lean rate.
According to a preferred embodiment, the first composition forms an event-driven dosing recommendation with endometrial proliferation as a starting node and endometrial atrophy as an ending node.
According to a preferred embodiment, the second composition constitutes an event driven dosing advice driven by the first composition event driven dosing advice with an endometrial shedding procedure as an intermediate node, wherein at least three states of presence of the endometrium, namely endometrial proliferation, endometrial atrophy, endometrial shedding, form a closed loop in such a way that a directed event driven dosing advice is formed for the first and second composition, and the first composition event driven dosing advice is caused to perform a restricted cycle on the event driven dosing advice for the second composition.
According to a preferred embodiment, the administration assistance system continuously provides the user with event-driven administration advice for administration of the first, ordered composition within a timeline in which endometrial proliferation is the starting node and endometrial atrophy is the ending node. The administration assistance system provides event-driven administration advice of the second composition that is conditioned on time-limited execution of the first composition event-driven administration advice and that is administered in the event of onset to end of endometrial prolapse.
The technical proposal has the advantages that: periodic psychosis does not produce symptoms in the event of endometrial proliferation as a starting node and endometrial atrophy as an ending node, but is affected by symptoms of the previous period of disease to form neurasthenia. The affected side effects have a certain effect on the patient's daily life and cause the body to reduce resistance to the next disease process in the cycle. During the cycle of the accumulation, patients who do not rely on the first composition for side effect alleviation lengthen the rhythm of the diseased cycle and negatively affect the physiological state.
Further, the endometrial change state is a closed loop process of proliferation without gaps, then atrophy, finally shedding and proliferation. The storage device, which is driven by the drug advice depending on the state of change of the endometrium, forms a closed loop based on this for the event-driven advice of taking the drug.
According to a preferred embodiment, the first and second compositions constituting the medicament for periodic psychosis are stored in the administration aid system in a manner independent of each other, wherein the administration aid system forms information related to the female physiological cycle in a manner that predicts the occurrence of an event of the endometrial physiological state for constituting a driving event of an event-driven administration recommendation of the first composition. The administration assistance system forms information related to the female physiological cycle in a manner that predicts the occurrence of an event of the endometrial physiological state for composing a driving event of an event-driven administration advice of the second composition satisfying a time-limited execution condition composed of the event-driven administration advice of the first composition.
The technical proposal has the advantages that: in the prior art, the related design takes the past self-endometrium physiological state of a user as a database as training sample data or test data, takes the female physiological change in medical test as a modeling template, forms a physiological cycle prediction model suitable for most females, and appears in the form of app and the like at a mobile phone terminal. Based on this, a predictive model capable of predicting endometrium is used, and the individual endometrium change is used as a database sample to correct the suitability of the predictive model for the individual, so that the administration assistance system can receive reasonable prediction results of the predictive model for the user's endometrium physiological state change, and is presented to the administration assistance system in the form of a predictive report, forming a replacement of the administration advice driven by the formation of the predictive report as an event change. The onset of periodic psychosis follows the operation of the female's physiology, whereas for many patients taking psychotics for a long period of time, which leads to a decrease in memory or inattention, it is extremely difficult to calculate and predict their own physiology, resulting in a failure to timely take the second composition, i.e. atypical psychotics, one to two days before the physiology to suppress the onset of psychosis. However, long-term administration of the second composition by the patient in the non-physiological period can interfere with normal operation of liver and kidney functions and brain tissues of the body, and accompanying statistics of the occurrence of mental diseases of the patient in the non-physiological period, the administration of the medicine in the period does not have corresponding medicine effect, and medicine waste is generated. Based on this, cyclic administration is necessary.
According to a preferred embodiment, the administration assistance system is capable of storing at least in a voice information receiving manner information of an event-driven administration recommendation of a first composition in which an endometrial physiological state is an event occurrence and a time-limited execution condition constituted by the event-driven administration recommendation of the first composition, and the event occurrence is generated by the endometrial physiological state as an event-driven administration recommendation of a second composition, such that the administration schedules of the first composition and the second composition stored in the administration assistance system are independent of each other, are related to administration behavior, and are stored in a manner generating a correlation with the event occurrence. The administration assistance system stores and processes administration information of the first composition and the second composition in an event-driven manner related to the physiological state of the endometrium in one or more of image acquisition, voice information reception, or three-dimensional spatial displacement perception.
The technical proposal has the advantages that: most users in the administration period are accompanied by mental state instability. In the process of taking the medicine, whether the medicine taking behavior is normal or not affects whether a user takes the medicine normally or not, and a certain mental state judging index can be provided for doctors. Thus, the administration assistance system can provide a basis for the physician to judge the mental state of the user in a way that stores the administration regimen (administration advice comprising the corresponding first and second compositions) in association with the physiological state of the endometrium and the administration behavior in association with the administration regimen. When the auxiliary system for taking medicine is used, displacement change of three-dimensional state, image and sound change in the environment are generated, and based on the acquisition of the change, the auxiliary system for taking medicine can assist in acquiring surrounding environment information. The administration assistance system is capable of storing information of occurrence of the first composition and the second composition from the endometrial physiological state generation event as an event driven administration recommendation.
According to a preferred embodiment, the administration assistance system comprises a smart medicine cartridge comprising a processor, a memory and a storage cartridge body. The storage case is configured to be capable of storing the first composition and the second composition separately. The memory is coupled to the processor and stores a program. The program is executed by the processor to cause the processor to perform operations. The storage box is used for hiding the processor and the memory and is controlled by the processor, and state switching is formed based on corresponding instructions of the processor when the processor executes operations.
The invention provides a medicine taking auxiliary method, which is used for realizing storage and taking of different kinds of medicines.
Drawings
FIG. 1 is a flow chart of the administration of a first composition and a second composition of the present invention;
FIG. 2 is a block diagram of a system for managing medication intake and patient behavior records in accordance with one embodiment of the present invention;
fig. 3 is a flow chart of a procedure generated by the storage device during interaction with the parent terminal, data read-write device and patient bracelet.
Detailed Description
The technical scheme of the invention is further described by the following specific embodiments. It will be apparent to those skilled in the art that the examples are merely to aid in understanding the invention and are not to be construed as a specific limitation thereof.
The functionality referred to herein can be implemented in a smart cartridge in one embodiment that may contain the necessary equipment in the program execution instructions, such as a computer. Furthermore, the modules corresponding to these functions can correspond to software, hardware, firmware, or any combination thereof.
The invention discloses a medicine taking auxiliary system, a medicine for treating periodic psychosis and a storage device for storing the medicine. Most of the medicines taken by the periodic psychosis in the prior art are taken by periodic peak values without considering the shaking of the emotional secretion hormone when the periodic illness changes. The dosing habit is that the periodic physiological state of the patient is uncontrollable and the synchronization of the change node and the dosing node cannot be achieved in daily life. One technical problem relates to how the administration switching node is co-located with event-driven mental cycle changes in a state of no physician guidance. The medicine-following administration mode of the intelligent medicine box is the most widely applied at present, doctors are disjointed from the control of the physiological state of the patients when the periodic psychotic patients are in home maintenance, so that medicine-taking advice becomes difficult, and predicted cyclic medicine-taking becomes a correct method for treating the periodic psychosis by means of equipment and programs to finish correct medicine-taking.
Aiming at the pathogenesis characteristics of the periodic psychosis, the incidence peak value is found to be concentrated in the process of female endometrium shedding and gradually falls along with the ending of the process of endometrium shedding until the endometrium enters the proliferation stage to restore to normal state, and the incidence is rapid and ended rapidly. The neurotransmitter secretion of the patient in a normal state is normal, and side effects of taking medicine in the processes of neurasthenia, insomnia and morbidity exist. The neurotransmitters of patients in the onset state are secreted abnormally, resulting in symptoms like hallucination, mania, aggression, etc. like schizophrenia.
The first composition is slowly ingested by the digestive system before and after endometrial ablation in a manner that reduces nervous tension in conjunction with the metaencephalic neurons. The second composition reduces mental activity during endometrial ablation in a manner that binds neurotransmitters. The storage means graphically provides to the user an event-driven medication recommendation consisting of an endometrial drop predicted by the medication assistance system, wherein the first composition event-driven medication recommendation constitutes a time-limited execution condition for the second composition event-driven medication recommendation.
FIG. 1 is a flow chart of a system for administering a first composition and a second composition. The storage device predicts the state change of the endometrium by adopting a prediction model formed by data accumulation, and the prediction model can predict the physiological state of the endometrium by taking time as a travelling track. While the endometrium is in proliferation, the predictive model can generate and send the state of the endometrium as a first predictive report to an execution unit of the storage device, as shown in step 110. In step 120, the storage receives a first predictive report of the onset of endometrial proliferation by the predictive model. When the first predictive report is turned on, it may indicate that the predictive model has received information data. After receiving the first predictive report, the storage device instructs the user of a recommendation to take the first composition, as shown in step 130, and opens the area to the user where the first composition is stored, enabling the user to take the first composition. The term "indicating" is meant to include guidance and monitoring of the process of taking the first composition by the user, i.e. to include the step of guiding the user to take the first composition, graphically detecting the user's medication intake, and monitoring the accuracy of the dosage in the manner of monitoring the total dosage change. After initiation of endometrial proliferation, the administration of the first composition of the storage device is suggested to be repeated in a prescribed manner over a regular time period, resulting in a sequential repeated cycle of steps 110, 120 and 130. Until the predicted outcome of the predictive model, i.e. the endometrial physiological status, changes from proliferation to atrophy and takes the onset of endometrial atrophy as a node, step 140 is formed. Step 140 sends a second prediction report for the prediction model. The end of endometrial proliferation and the onset of endometrial atrophy constitute a second predictive report. The second predictive report is received in the same manner as the first predictive report, step 150, and enables the execution unit to make the recommended execution of the medication of the first composition without any instruction change. Execution of the non-altering instructions involved in step 160 includes any mechanical behavior that may occur during the administration of the first composition. Further, due to the physiological change law of endometrium, the second prediction report in step 140 can be regularly generated and sent to the execution unit, and the execution unit can receive the first composition in a single receiving manner in step 150 and regularly execute the administration advice of the first composition according to the number of times of receiving. The key node of the method is that the generation and the sending of a third prediction report are realized by driving an execution unit to generate different decisions in a mode of changing the physiological state of endometrium, namely, changing an event and forming a report. The third predictive report contains predictive information for the change of the predictive model from the atrophic state to the abscisic state for the endometrium and starting with the abscisic state as a time node for sending the third predictive report as shown in step 170. The execution unit receives the third prediction report and forms the execution operations as in steps 190 and 200. The third predictive report is configured to communicate to the execution unit an instruction to terminate the medication recommendation for the first composition and to drive the execution of the medication recommendation for the second composition by the execution unit with the termination of the medication recommendation for the first composition as a limit. Likewise, the advice of taking the second composition can instruct the user to take the second composition and open the area for storing the second composition to the user with the first composition storage area closed, so that the user can perform the taking operation of the second composition.
As shown in step 200, the time node at which the execution unit receives the third predictive report can be formed in order of time as an occurrence element with the start node at which the medication recommendation of the second composition is performed to receive the third predictive report as a priority.
The first composition event-driven dosing recommendation constitutes a time-limited execution condition of the event-driven dosing recommendation of the second composition. Based on the irreversibility of the change in physiological state of the endometrium, endometrial proliferation in the first predictive report can occur before endometrial atrophy in the second predictive report can occur before endometrial prolapse in the third predictive report, and so on. And after the endometrium falls off, a new endometrium grows again and the proliferation process is continued, so that the physiological change process of the endometrium in a normal state is realized. With the physiological change of the endometrium, an event-driven medicine taking proposal decision program is formed by taking the start and the end of each stage in the physiological change process of the endometrium as anchor points and taking the change state of the endometrium as the driving of program execution.
The execution unit receives the first predictive report based on the change in the preamble received by the third predictive report, and the execution unit executes termination of the recommendation for taking the second composition. When the execution unit tries to enter the next cycle, the predictive model is required to send a first detection report as a trigger instruction.
The storage device which implements the program and includes the execution unit can be connected to a computer device on which a prediction model is loaded by using a wireless network as a transmission channel, and can realize network transmission of a prediction report. Can be used for pharmaceutical compositions. Fig. 2 is a block diagram of a system for managing medication intake and patient behavior records, according to an example embodiment. The device is used for carrying out wired or wireless data reading on the storage device and the bracelet through a network, so that a doctor can process the illness state of a patient based on the data in the diagnosis or re-diagnosis process. A wristband that monitors the patient's behavioral operations is worn at the patient's wrist and is based on the sensing of the stored device indirectly through a connection to the network. The guardian terminal is used for receiving information of the storage device and receiving information sent by the storage device through a terminal basic communication function or an upper program app based on connection with a network. The guardian's terminal can be a cell phone, computer, tablet or other device. The network can be the internet, a private network, a data network, or other type of network that facilitates the transfer of information between devices. Preferably, the guardian can be provided with two at least, wears guardian A's terminal and guardian B's terminal respectively, and the terminal of both can be connected with intelligent medicine box through the network to avoid the information communication obstacle that single guardian caused, can't arrive the patient in time and arrive at the patient and arrive at the side and cause the unexpected problem of patient in time because of individual reason.
According to a preferred embodiment, the smart kit is capable of collecting the patient's operational behavior of the smart kit. Fig. 3 shows a flow chart of a procedure generated by the storage device during interaction with the parent terminal, the data read-write device and the patient's bracelet. The intelligent medicine box stores the operation behaviors in the intelligent medicine box storage area in a data information mode along the time track sequence. In the case where the operational behavior associated with the medication intake is determined based on the data information analysis, the smart kit generates verification information that is related to the medication intake information of the patient. The information of single medicine taking is stored in a storage area in a set mode, the intelligent medicine box carries out intersection processing on the set of medicine taking information, and when the abnormal behavior quantity set presented in the intersection is larger than the abnormal behavior quantity threshold value set by a doctor in the intelligent medicine box, the intelligent medicine box in a locking state sends a review suggestion to a guardian in a mode of carrying out patient abnormal behavior information analysis result transmission to a guardian terminal of a guardian not accompanied with the patient. The intelligent medicine box can judge whether the guardian accompanies the patient by positioning whether the guardian terminal exists in the signal detection range. When judging that the abnormal behavior of the patient does not accord with the behavior state displayed by the current disease degree of the bipolar affective disorder, the intelligent medicine box can be automatically locked, so that the problems of medicine poisoning caused by violent damage to the medicine box and medicine misuse under the overdriving behavior of the patient are prevented.
It should be noted that the above-described embodiments are exemplary, and that a person skilled in the art, in light of the present disclosure, may devise various solutions that fall within the scope of the present disclosure and fall within the scope of the present disclosure. It should be understood by those skilled in the art that the present description and drawings are illustrative and not limiting to the claims. The scope of the invention is defined by the claims and their equivalents.
Claims (8)
1. A medicine taking auxiliary system comprising a medicine for treating periodic psychosis and a storage device for storing the medicine, characterized in that,
the drug for periodic psychosis comprises a first composition which is slowly ingested by the digestive system before and after the shedding of endometrium in a manner of reducing nervous tension in combination with the metaencephalon neurons and a second composition which reduces the activity of thinking in a manner of combining neurotransmitters during the shedding of endometrium,
the administration assistance system graphically providing to a user an event-driven administration recommendation consisting of an endometrial drop predicted by the administration assistance system, wherein the first composition event-driven administration recommendation constitutes a time-limited execution condition of the second composition event-driven administration recommendation,
the first composition constitutes an event-driven dosing recommendation compliant with a treatment regimen in such a way that the dosing assistance system initiates endometrial proliferation and the endometrial atrophy forms a time-dependent treatment regimen as an end node,
the administration assistance system provides event-driven administration advice of the second composition that is conditioned on time-limited execution of the first composition event-driven administration advice and that is administered in an event from initiation to termination of endometrial prolapse.
2. The taking assistance system of claim 1, wherein the second composition forms an event driven taking recommendation driven by the first composition event driven taking recommendation with an onset of endometrial shedding as an intermediate node, wherein at least three states of endometrial presence, i.e., endometrial proliferation, endometrial atrophy, endometrial shedding, form a closed loop in a manner that forms a guided event driven taking recommendation for the first and second compositions, and cause the first composition event driven taking recommendation to perform a restricted cycle on the second composition event driven taking recommendation in a manner that the taking assistance system performs image presentation.
3. The medication assistance system of claim 1, wherein the medication assistance system continuously provides the user with event-driven medication advice for administration within a timeline in which the first composition is ordered to proliferate endometrium as a starting node and shrink endometrium as an ending node.
4. The medication assistance system according to claim 1, wherein the first and second compositions comprising the drug of the periodic psychosis are stored in the medication assistance system independently of each other, wherein the medication assistance system forms information related to the female physiological cycle in a manner that predicts the occurrence of an event of an endometrial physiological state for composing a driving event of an event driven medication recommendation of the first composition.
5. The medication assistance system of claim 4 wherein the medication assistance system forms information related to a female physiological cycle in a manner that predicts the occurrence of an event in an endometrial physiological state for composing a driving event for an event-driven medication recommendation for a second composition that satisfies a time-limited execution condition for the composition of the first composition event-driven medication recommendation.
6. The medication assistance system of claim 1, wherein the medication assistance system is capable of storing, at least in a manner of voice information reception, event-driven medication advice of a first composition that is incident to an endometrial physiological state and time-limited execution conditions constituted by the event-driven medication advice of the first composition, and generating information of the event-driven medication advice of a second composition that is incident to the endometrial physiological state such that the event-driven medication advice of the first composition and the second composition stored in the medication assistance system independent of each other are correlated with the medication behavior and are stored in a manner that correlates with the occurrence of the event.
7. The medication assistance system of claim 1, wherein the medication assistance system stores and processes the first and second compositions of event-driven medication information related to endometrial physiological status in one or more of image acquisition, voice information reception, or three-dimensional spatial displacement perception.
8. A medication assistance method, characterized in that different kinds of medicines are stored and taken by using the medication assistance system according to any one of claims 1 to 7.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202110999179.6A CN113689931B (en) | 2021-08-25 | 2021-08-25 | Auxiliary system and method for taking medicine |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202110999179.6A CN113689931B (en) | 2021-08-25 | 2021-08-25 | Auxiliary system and method for taking medicine |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN113689931A CN113689931A (en) | 2021-11-23 |
| CN113689931B true CN113689931B (en) | 2024-01-26 |
Family
ID=78583597
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202110999179.6A Active CN113689931B (en) | 2021-08-25 | 2021-08-25 | Auxiliary system and method for taking medicine |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN113689931B (en) |
Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101313908A (en) * | 2007-05-31 | 2008-12-03 | 北京世纪博康医药科技有限公司 | Composition for treating autonomic nerve disorder, preparation and uses thereof |
| CN102008688A (en) * | 2010-12-09 | 2011-04-13 | 上海市精神卫生中心 | Medicament for treating periodic psychosis |
| CN105233029A (en) * | 2015-10-16 | 2016-01-13 | 岳永磊 | Chinese and western medicine compound preparation for premenstrual syndrome |
| CN110111865A (en) * | 2019-05-05 | 2019-08-09 | 上海市嘉定工业区社区卫生服务中心(上海市嘉定工业区地段医院) | A kind of method and system being automatically reminded to medication |
| CN111655128A (en) * | 2018-02-09 | 2020-09-11 | 德克斯康公司 | System and method for decision support |
| CN112889114A (en) * | 2018-10-31 | 2021-06-01 | 美敦力泌力美公司 | Automated detection of physical behavioral events and corresponding adjustment of drug dispensing systems |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20050176693A1 (en) * | 2003-08-12 | 2005-08-11 | Boissonneault Roger M. | Method of intermittent administration of a pharmaceutical for the treatment of conditions associated with a female's menstrual cycle |
| WO2006012563A2 (en) * | 2004-07-23 | 2006-02-02 | The Regents Of The University Of California | Method for the treatment and diagnosis of certain psychiatric disorders related to the menstrual cycle |
-
2021
- 2021-08-25 CN CN202110999179.6A patent/CN113689931B/en active Active
Patent Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101313908A (en) * | 2007-05-31 | 2008-12-03 | 北京世纪博康医药科技有限公司 | Composition for treating autonomic nerve disorder, preparation and uses thereof |
| CN102008688A (en) * | 2010-12-09 | 2011-04-13 | 上海市精神卫生中心 | Medicament for treating periodic psychosis |
| CN105233029A (en) * | 2015-10-16 | 2016-01-13 | 岳永磊 | Chinese and western medicine compound preparation for premenstrual syndrome |
| CN111655128A (en) * | 2018-02-09 | 2020-09-11 | 德克斯康公司 | System and method for decision support |
| CN112889114A (en) * | 2018-10-31 | 2021-06-01 | 美敦力泌力美公司 | Automated detection of physical behavioral events and corresponding adjustment of drug dispensing systems |
| CN110111865A (en) * | 2019-05-05 | 2019-08-09 | 上海市嘉定工业区社区卫生服务中心(上海市嘉定工业区地段医院) | A kind of method and system being automatically reminded to medication |
Also Published As
| Publication number | Publication date |
|---|---|
| CN113689931A (en) | 2021-11-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Di Perri et al. | Functional neuroanatomy of disorders of consciousness | |
| Schiff et al. | Behavioural improvements with thalamic stimulation after severe traumatic brain injury | |
| Hampson et al. | Facilitation and restoration of cognitive function in primate prefrontal cortex by a neuroprosthesis that utilizes minicolumn-specific neural firing | |
| Inglis et al. | Dopaminergic innervation of the amygdala is highly responsive to stress | |
| Lane et al. | Acute marijuana effects on human risk taking | |
| Abel et al. | Low dose ketamine increases prepulse inhibition in healthy men | |
| DE69918333T2 (en) | SYSTEM FOR SUPPORTING A MEDICAL SELF-TREATMENT, WHICH CONTAINS A MULTIPLE OF STEPS | |
| Chiamulera | Cue reactivity in nicotine and tobacco dependence: a “multiple-action” model of nicotine as a primary reinforcement and as an enhancer of the effects of smoking-associated stimuli | |
| Asadi-Pooya | Drug compliance of children and adolescents with epilepsy | |
| Usmani et al. | Association between paroxysmal tonic spasms and neuromyelitis optica | |
| Yu et al. | Theories of impaired consciousness in epilepsy | |
| DE112020004780T5 (en) | BLOOD SUGAR CONTROL SYSTEM | |
| Karayanidis et al. | Switching between univalent task-sets in schizophrenia: ERP evidence of an anticipatory task-set reconfiguration deficit | |
| LIBERMAN et al. | Drugs and behavior analysis | |
| Fridman et al. | Organizing a rational approach to treatments of disorders of consciousness using the anterior forebrain mesocircuit model | |
| Foltin et al. | Modafinil decreases cocaine choice in human cocaine smokers only when the response requirement and the alternative reinforcer magnitude are large | |
| CN113689931B (en) | Auxiliary system and method for taking medicine | |
| Myers | Psychotherapy for substance use disorders | |
| Becker et al. | The efficacy of lidocaine in disrupting cocaine cue-induced memory reconsolidation | |
| Matuskey et al. | A single-day paradigm of self-regulated human cocaine administration | |
| Bloch et al. | The acupuncture treatment of schizophrenia: A review with case studies | |
| CN113662857A (en) | Medicine storage system and method | |
| Joshi et al. | Yawning induced by focal electrical stimulation in the human brain | |
| Zahner et al. | Physiological approaches to assess diminished sympathetic activity in the conscious rat | |
| Case et al. | A Practical Guide to Supporting People with Epilepsy |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |